ArticleDiabetes, obesity & metabolism2026
SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
aimsSemaglutide is a GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. Its clinical effects are well established, but the underlying mechanisms remain unclear. This study aims to use computational modelling to generate hypotheses about semaglutide's long-term metabolic (body weight, net energy intake, blood glucose, insulin, insulin sensitivity, glucotoxicity, leptin, leptin sensitivity, lipotoxicity, GLP-1 and βcell function) and neural (AgRP, POMC, and dopamine neural activity) effects. MATERIALS AND
methodsThe SemaGBA computational model was developed in Julia using a system dynamics approach, integrating 14 metabolic and neural variables. First, a version without neural variables was constructed and validated against clinical data for blood glucose and weight loss. Subsequently, the model was extended with neural variables. To represent distinct population groups, baseline variable profiles were defined, capturing the typical physiological characteristics for people with type 2 diabetes, obesity, and a healthy condition. Simulations were performed for semaglutide treatment in groups with prediabetes induced by chronic overeating, type 2 diabetes, and obesity over periods ranging from 30 weeks to 5 years.
resultsThe reduced model accurately reproduced clinical outcomes. It predicts glucose reductions of 38.0 mg/dL (data: 41.0 mg/dL) and weight loss of 3.2 kg (data: 3.8 kg) for diabetes (0.5 mg semaglutide), and 15.1% weight loss (data: 14.9%-17.1%) for obesity (2.4 mg semaglutide). Simulations showed semaglutide's interconnected mechanisms, including reduced lipotoxicity and glucotoxicity, enhanced β-cell function, and glucose-dependent insulin secretion. Intervention during prediabetes prevented progression to diabetes by preserving β-cell function and maintaining glucose in the pre-diabetic range. Neural variables illustrated the potential contribution of AgRP, POMC, and dopamine neuron activity to reduced net energy intake.
conclusionThe SemaGBA model demonstrates how semaglutide achieves glucose control and weight loss through integrated metabolic and neural pathways. Validation is limited by data availability, but the framework provides hypotheses for future research into semaglutide's neural effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.